Sean J Mulvihill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11297435/publications.pdf

Version: 2024-02-01

59 papers	3,891 citations	201674 27 h-index	144013 57 g-index
65 all docs	65 docs citations	65 times ranked	6860 citing authors

#	Article	IF	Citations
1	Hospital Costs Following Surgical Complications. Annals of Surgery, 2022, 275, e375-e381.	4.2	14
2	Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. Clinical Cancer Research, 2022, 28, 1938-1947.	7.0	11
3	Value Analysis of Methods of Inguinal Hernia Repair. Annals of Surgery, 2021, 274, 572-580.	4.2	5
4	Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. Neoplasia, 2021, 23, 859-869.	5.3	6
5	Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. Annals of Surgical Oncology, 2020, 27, 333-341.	1.5	38
6	County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma. Annals of Surgery, 2020, 272, 1102-1109.	4.2	9
7	Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report. Journal of Pancreatic Cancer, 2019, 5, 22-25.	0.9	4
8	Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. Surgery, 2019, 165, 751-759.	1.9	43
9	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nature Communications, 2019, 10, 254.	12.8	120
10	Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. Journal of Gastrointestinal Surgery, 2019, 23, 1401-1413.	1.7	7
11	Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma. Annals of Surgery, 2019, 269, 133-142.	4.2	15
12	Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. Surgery, 2018, 163, 753-760.	1.9	14
13	Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?. Surgery, 2018, 164, 1178-1184.	1.9	39
14	Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer, 2018, 18, 697.	2.6	29
15	Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma. JAMA Oncology, 2018, 4, 1129.	7.1	14
16	Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery, 2017, 162, 104-111.	1.9	13
17	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, djw266.	6.3	116
18	A nomogram to predict pathologic lymph node positivity in clinical stage I-II pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 382-382.	1.6	1

#	Article	IF	Citations
19	Biomarkers in pancreatic adenocarcinoma: current perspectives. OncoTargets and Therapy, 2016, Volume 9, 7459-7467.	2.0	72
20	Early Detection of Sporadic Pancreatic Cancer. Pancreas, 2015, 44, 693-712.	1.1	255
21	Defective apical extrusion signaling contributes to aggressive tumor hallmarks. ELife, 2015, 4, e04069.	6.0	59
22	Value Driven Outcomes (VDO): a pragmatic, modular, and extensible software framework for understanding and improving health care costs and outcomes. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 223-235.	4.4	95
23	Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation. Journal of Gastrointestinal Surgery, 2015, 19, 1813-1821.	1.7	21
24	Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. Hpb, 2014, 16, 670-676.	0.3	48
25	The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nature Cell Biology, 2014, 16, 255-267.	10.3	172
26	Screening for Pancreatic Cancer. Advances in Surgery, 2014, 48, 115-136.	1.3	20
27	Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. Theoretical Biology and Medical Modelling, 2014, 11, 34.	2.1	16
28	Pancreatic Adenocarcinoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1083-1093.	4.9	307
29	Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel. Analyst, The, 2013, 138, 410-416.	3.5	87
30	Serum Osteopontin and Tissue Inhibitor of Metalloproteinase 1 as Diagnostic and Prognostic Biomarkers for Pancreatic Adenocarcinoma. Pancreas, 2013, 42, 193-197.	1.1	86
31	Screening for Pancreatic Cancer. Annals of Surgery, 2013, 257, 17-26.	4.2	217
32	Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression. Cancer Cell, 2011, 19, 441-455.	16.8	452
33	Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. Hpb, 2010, 12, 352-358.	0.3	13
34	Phenotype and Genotype of Pancreatic Cancer Cell Lines. Pancreas, 2010, 39, 425-435.	1.1	746
35	Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2605-2610.	2.5	55
36	A Population-Based Description of Familial Clustering of Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2010, 8, 812-816.	4.4	19

#	Article	IF	Citations
37	Improved Diagnosis of Pancreatic Adenocarcinoma Using Haptoglobin and Serum Amyloid A in a Panel Screen. World Journal of Surgery, 2009, 33, 716-722.	1.6	51
38	ACS-NSQIP has the potential to create an HPB-NSQIP option. Hpb, 2009, 11, 405-413.	0.3	108
39	Synthetic Extracellular Matrix Enhances Tumor Growth and Metastasis in an Orthotopic Mouse Model of Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, 2008, 12, 1074-1080.	1.7	28
40	Natural History of Pancreatic Cancer Recurrence Following â€œCurativeâ€•Resection in Athymic Mice. Journal of Surgical Research, 2008, 149, 57-61.	1.6	12
41	Pancreatic Resection in Veterans Affairs and Selected University Medical Centers: Results of the Patient Safety in Surgery Study. Journal of the American College of Surgeons, 2007, 204, 1252-1260.	0.5	56
42	Development of a Dedicated Hepatopancreaticobiliary Program in a University Hospital System. Journal of Gastrointestinal Surgery, 2005, 9, 891-895.	1.7	16
43	The benefits of a dedicated minimally invasive surgery program to academic general surgery practice. Journal of Gastrointestinal Surgery, 2004, 8, 869-873.	1.7	14
44	Surgical management of gallstone disease and postoperative complications. Seminars in Gastrointestinal Disease, 2003, 14, 237-44.	0.8	8
45	Laparoscopic Splenectomy. World Journal of Surgery, 1999, 23, 384-388.	1.6	30
46	Percutaneous Management of Abscess and Fistula Following Pancreaticoduodenectomy. CardioVascular and Interventional Radiology, 1999, 22, 25-28.	2.0	13
47	Hepatocyte Growth Factor Stimulates Fetal Gastric Epithelial Cell Growthin Vitro. Journal of Surgical Research, 1998, 78, 161-168.	1.6	14
48	Prognostic Factors in Pancreatic Carcinoma. Surgical Oncology Clinics of North America, 1997, 6, 533-554.	1.5	12
49	Perioperative Use of Octreotide in Gastrointestinal Surgery. Digestion, 1993, 54, 33-37.	2.3	7
50	Selective Release of Somatostatin by Calcitonin Gene?Related Peptide and Influence on Pancreatic Secretion. Annals of the New York Academy of Sciences, 1992, 657, 289-298.	3.8	6
51	Improvement in survival of mice with proximal small bowel obstruction treated with octreotide. American Journal of Surgery, 1992, 163, 231-233.	1.8	11
52	Neuroendocrine design of the gut. American Journal of Surgery, 1991, 161, 243-249.	1.8	57
53	Somatostatin inhibits pancreatic exocrine secretion via a neural mechanism. Metabolism: Clinical and Experimental, 1990, 39, 143-148.	3.4	31
54	Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells. Journal of Surgical Research, 1989, 46, 327-329.	1.6	18

#	Article	IF	Citations
55	Surgical Approach to Functional Bowel Disease. , 1989, , 335-355.		0
56	The Effect of Somatostatin on Experimental Intestinal Obstruction. Annals of Surgery, 1988, 207, 169-173.	4.2	30
57	Trophic effect of amniotic fluid on fetal gastrointestinal development. Journal of Surgical Research, 1986, 40, 291-296.	1.6	115
58	Pyloroplasty in infancy and childhood. Journal of Pediatric Surgery, 1983, 18, 930-936.	1.6	13
59	Surgery for Peptic Ulcer Disease and Postgastrectomy Syndromes. , 0, , 276-282.		1